Sage Therapeutics Receives Acquisition Proposal from BiogenCAMBRIDGE, Mass., January 10, 2025 — Sage Therapeutics, Inc. (NASDAQ: SAGE) recently disclosed that it has received an unsolicited and non-binding acquisition proposition from Biogen Inc. The

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sage Therapeutics’s 8K filing here.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.